As of right now, Surgery Partners Inc. [SGRY] is trading at $35.94, up 3.69%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SGRY shares have gain 11.06% over the last week, with a monthly amount glided 36.65%, and seem to be holding up well over a long-time horizon.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
On 9, January 2023, Surgery Partners, Inc. Reaffirms 2022 Full Year Guidance. In a post published today on Yahoo Finance, Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 9, 2023, as part of the 41st Annual J.P. Morgan Healthcare Conference, including a presentation at 8:15 p.m. ET. Based on results through November 2022, the Company is re-affirming its 2022 Adjusted EBITDA guidance of $375 million to $385 million and its 2022 Revenue guidance of $2.50 billion to $2.55 billion.
From an analyst’s perspective:
Surgery Partners Inc. [NASDAQ: SGRY] stock has seen the most recent analyst activity on November 23, 2022, when RBC Capital Mkts reiterated its Outperform rating and also revised its price target to $48 from $58. Previously, BofA Securities downgraded its rating to Neutral on June 15, 2022, and dropped its price target to $36. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $73 on November 30, 2021. Stifel upgraded its rating to a Buy but $51 remained the price target by the analyst firm on November 29, 2021. JP Morgan started tracking with a Neutral rating for this stock on November 01, 2021, and assigned it a price target of $50. In a note dated October 18, 2021, SVB Leerink initiated an Outperform rating and iterated a target price of $50 on this stock.
Through the last year, Surgery Partners Inc.’s stock price ranged from $20.46 to $63.87. Surgery Partners Inc. [NASDAQ: SGRY] shares were valued at $35.94 at the most recent close of the market.
Analyzing the SGRY fundamentals
For Surgery Partners Inc., (SGRY), the latest quarter sales were 620.6 billion, which represents an 11.00% increase.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.28 points at the first support level, and at 34.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.46, and for the 2nd resistance point, it is at 36.97.
Surgery Partners Inc. [SGRY] reported earnings per share of -$0.03 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.01/share, meaning a difference of -$0.02 and a surprise factor of -200.00%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.09 per share as compared to estimates of -$0.06 per share, a difference of -$0.03 representing a surprise of -50.00%.
Ratios To Look Out For
It is important to note that Surgery Partners Inc. [NASDAQ:SGRY] has a current ratio of 1.20.
Transactions by insiders
We now turn our attention to insider trading, which in the past 3 months has resulted in 5 insider buyings of 27,581,019 shares and 1 insider sellings of 4,338 shares. Recent insider trading involved TURNER BRENT, Director, that happened on Nov 21 when 10000.0 shares were purchased. Director, DeLuca Teresa completed a deal on Nov 21 to buy 20000.0 shares. Meanwhile, Chief Human Resources Officer Brocklehurst Laura L. sold 4338.0 shares on Nov 09.